KVAL: Artificial liver organoids

The innovative method is suitable for large-scale production of vascularized liver organoids comprising differentiated hepatocytes. Furthermore, the method is suitable for upscaling and can be performed based on supplementing culture media with small molecules only. The products may serve as an inexpensive approach to produce massive quantities of liver organoids with enhanced function and maturity, which, in turn, may be useful for a variety of applications from cellular therapy, tissue engineering, drug toxicity assessment, disease modelling, and basic developmental research. The market potential was evaluated and mapped. We initiated partnering discussions and this resulted in a conclusion of out-licensing the technology to a small biotech company.

The market potential was evaluated and mapped. We initiated partnering discussions to explore a better market fit and to achieve a benchmarking of terms that resulted in a conclusion of out-licensing to a small biotech company.